

Current Report No 29

Receipt of the decision on granting patent protection for the proprietary set of primers, diagnostic method, and the use of primer set for HPV infection detection to genetically diagnose HPV16 (Human papillomavirus type 16) in the territory of Republic of Poland.

The Executive Board of Genomtec S.A. („Company”, „Issuer”) registered in Wrocław, Poland, hereby reports that the Republic of Poland Patent Office has positively opined to grant the Company a patent protection for an invention entitled "A set primers to detect Human papillomavirus type 16, diagnostic method to detect HPV16, use of primer set for HPV infection detection".

The Issuer informs that this is the fourth patent granted by the Republic of Poland Patent Office and the sixth patent secured by the Company. The Issuer is pending over twenty patent applications globally.

HPV 16 is one of the sexually transmitted viruses belonging to the human papillomavirus family. Because of its oncogenic properties, it is one of the main causes of cervical cancer. Early diagnosis of HPV infection will allow prompt initiation of appropriate therapeutic and diagnostic procedures and further monitoring of the patient in order to reduce the risk of cancer development or its rapid diagnosis and further treatment.

The Issuer's Management Board decided that the acknowledgement of the above patent is a confidential information, as in the case of an entity operating on the molecular diagnostics market, it is necessary to effectively protect intellectual property and designs. Properly secured intellectual property and designs may constitute the Issuer's competitive advantage, allowing safer commercialization under condition that full protection is ensured on selected markets.

In the opinion of the Management Board, a high level of intellectual property protection will also provide the Company with an advantageous negotiating position before signing any commercial contracts with selected partners as part of the commercialization strategy implementation.



Patent proceedings are aimed at securing key interests and are in line with the Issuer's development strategy, which includes building a portfolio of intellectual property rights. Diagnosis of viral infections is one of the key areas of technology developed by the Issuer.

For these reasons, in the opinion of the Management Board, this information meets the criteria of confidential information described in Art. 17 sec. 1 MAR.